Drug intelligence / Profile preview

FAP-CAR-ΔTGFβRII

Development stage: Preclinical
Lead developer: University of Pennsylvania
Modality: CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

**FAP-CAR-ΔTGFβRII** is a preclinical, mRNA-encoded CAR-macrophage construct designed to target fibroblast activation protein alpha on cancer-associated fibroblasts while co-expressing a dominant-negative transforming growth factor beta receptor 2 module. FAP-directed CAR activity is intended to enable macrophage-mediated elimination of fibroblast activation protein alpha-positive stromal cells, whereas the truncated transforming growth factor beta receptor 2 blocks immunosuppressive transforming growth factor beta signaling and reduces profibrotic activity. The construct was developed as one component of an intravenously delivered lipid nanoparticle mRNA system that generated in vivo CAR-macrophages in mouse hepatocellular carcinoma models; it was co-administered with GPC3-CAR-Super IL-2 in the quadrivalent LNP-GF CAR regimen. ([biorxiv.org](https://www.biorxiv.org/content/biorxiv/early/2024/11/08/2024.11.06.621821.full.pdf))

Other names: FAP-CAR-△TGFβRII

Targets

FAP (Fibroblast activation protein alpha)TGFBR2 (TGF-β receptor type 2)

Beyond the preview

Go deeper on FAP-CAR-ΔTGFβRII.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAP-CAR-ΔTGFβRII.

Explore the full profile